San Mateo, CA, United States of America

Albert Frederick Candia, Iii

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Dynavax Technologies Corporation. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Albert Frederick Candia, Iii. Retrieved from https://idiyas.com/inventor/albert-frederick-candia-iii

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Albert Frederick Candia, III

Introduction

Albert Frederick Candia, III is an accomplished inventor based in San Mateo, California. With a remarkable focus on immunology, he has made significant contributions to the field through his innovative patent work. His inventions are paving the way for new therapeutic approaches to modulating immune responses.

Latest Patents

Albert holds two notable patents, both of which pertain to toll-like receptor antagonist compounds and methods of use. These inventions involve compounds described as formula (I), or their salts or solvates, which exhibit antagonistic activity against toll-like receptors such as TLR7, TLR8, and TLR9. The pharmaceutical compositions derived from these compounds are designed to inhibit undesirable immune responses and treat diseases associated with these conditions.

Career Highlights

Albert is currently associated with Dynavax Technologies Corporation, a prominent player in the biotechnology sector. His work focuses on advancing the understanding of immune modulation and the therapeutic potential of toll-like receptor antagonists.

Collaborations

During his career, Albert has collaborated with esteemed professionals in the field, including Richard Thomas Beresis and Robert L. Coffman. Together, they have contributed to the shared goal of pushing the boundaries of immunology and developing innovative treatments.

Conclusion

Albert Frederick Candia, III stands out as a visionary inventor whose work in toll-like receptor antagonism plays a critical role in the ongoing quest for advanced immune therapies. His dedication and innovative spirit continue to inspire advancements in immunological research and treatment methods.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…